Targovax ASA: First quarter 2022 results
Oslo, Norway, 12 May 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target…
Börse:
1,556$
1,05%
Echtzeit-Aktienkurs Agenus Inc.
Bid:
1,535$
Ask:
1,578$
Nachrichtenticker der Agenus Inc. Aktie
Targovax ASA: First quarter 2022 results
Oslo, Norway, 12 May 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2022 results. Members of Targovaxs executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).
1Q 2022 HIGHLIGHTS
Business Development
· Announced two key collaboration agreements with Agenus:
· Free drug supply of two checkpoint inhibitors for ONCOS-102 combination therapy in the upcoming phase 2 melanoma trial...
Den vollständigen Artikel können Sie lesen unter: https://news.cision.com/targovax/r/targovax-asa--first-quarter-2022-results,c3565538.
1Q 2022 HIGHLIGHTS
Business Development
· Announced two key collaboration agreements with Agenus:
· Free drug supply of two checkpoint inhibitors for ONCOS-102 combination therapy in the upcoming phase 2 melanoma trial...
Den vollständigen Artikel können Sie lesen unter: https://news.cision.com/targovax/r/targovax-asa--first-quarter-2022-results,c3565538.